Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tyra Biosciences Inc (TYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: TYRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.91% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 410.92M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 337211 | Beta 1.19 | 52 Weeks Range 7.52 - 29.60 | Updated Date 04/6/2025 |
52 Weeks Range 7.52 - 29.60 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date 2025-03-28 | When - | Estimate -0.4671 | Actual -0.43 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.09% | Return on Equity (TTM) -31.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75697267 | Price to Sales(TTM) - |
Enterprise Value 75697267 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.95 | Shares Outstanding 53090000 | Shares Floating 21075120 |
Shares Outstanding 53090000 | Shares Floating 21075120 | ||
Percent Insiders 4.17 | Percent Institutions 95.73 |
Analyst Ratings
Rating 4.71 | Target Price 30.57 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tyra Biosciences Inc
Company Overview
History and Background
Tyra Biosciences, Inc. is a precision oncology company founded in 2018. It focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. It has rapidly progressed through preclinical stages to clinical trials with its lead programs.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing small molecule therapeutics targeting specific cancer-driving mutations.
- Precision Oncology: Develops therapies based on a deep understanding of the molecular basis of cancer and patient stratification.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced executives in drug development and oncology. The organizational structure typically includes departments for research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- TYRA-300: An FGFR3-selective inhibitor targeting advanced urothelial carcinoma and other FGFR3-altered cancers. It is in clinical trials. Competitors include FGFR inhibitors developed by Johnson & Johnson (erdafitinib - Balversa) and others. Market share data is currently not available as TYRA-300 is in clinical development.
- TYRA-200: Next generation RET inhibitor. Competitors include Eli Lilly's Retevmo (selpercatinib) and Blueprint Medicines' Gavreto (pralsetinib). Market share data is currently not available as TYRA-200 is in preclinical development.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market driven by increasing cancer incidence and advancements in cancer therapies. Precision oncology is a growing segment, focusing on targeted therapies for specific genetic mutations.
Positioning
Tyra Biosciences is positioned as a precision oncology company developing novel small molecule therapeutics. Its competitive advantage lies in its focus on overcoming drug resistance and its expertise in kinase inhibitor design.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is significant, estimated to be in the tens of billions of dollars. Tyra is positioning itself to capture a share of this market by developing targeted therapies for specific patient populations with unmet needs.
Upturn SWOT Analysis
Strengths
- Strong focus on precision oncology and targeted therapies
- Experienced management team
- Proprietary drug discovery platform
- Focus on overcoming drug resistance
Weaknesses
- Limited clinical data to date
- Dependence on successful clinical trials
- High R&D expenses
- Relatively small company size
Opportunities
- Potential to develop first-in-class or best-in-class therapies
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Advancements in cancer diagnostics and patient stratification
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn impacting R&D spending
Competitors and Market Share
Key Competitors
- LLY
- BMY
- JNJ
Competitive Landscape
Tyra Biosciences competes with larger pharmaceutical companies with established oncology portfolios. Its advantage lies in its focus on specific cancer-driving mutations and its potential to develop novel therapies that overcome drug resistance. TYRA's disadvantage is lack of established products/sales compared to larger Pharma.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progress of its drug candidates through preclinical and clinical development.
Future Projections: Future growth projections are based on analyst estimates of peak sales potential for its drug candidates if approved. These projections are highly speculative.
Recent Initiatives: Recent initiatives include advancing TYRA-300 in clinical trials, progressing TYRA-200 through IND-enabling studies, and expanding its pipeline of targeted therapies.
Summary
Tyra Biosciences is a clinical-stage precision oncology company with promising drug candidates targeting specific cancer mutations. The company has an experienced management team. Key risks include clinical trial failures, competition from established players, and high R&D spending. Successful clinical trial results and strategic partnerships are critical for its future growth.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
GTHX
G1 Therapeutics Inc
GTHX
G1 Therapeutics Inc
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence. Market share data for clinical-stage companies is limited and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tyra Biosciences Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-09-15 | Co-Founder, President, CEO, Secretary, Treasurer & Director Dr. Todd Harris Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://tyra.bio |
Full time employees 60 | Website https://tyra.bio | ||
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.